ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.

Artificial intelligence is accelerating breakthroughs in G protein-coupled receptor (GPCR) research, a key area for developing new medicines. From predicting complex receptor structures to screening ...

Abstract: Cancer therapy peptides (CTPs), as multifunctional peptides, possess the ability to target cancer cells or related proteins, exhibiting significant therapeutic potential. However, ...

A detailed new map of the human kidney revealed a previously unrecognized form of diabetic kidney disease (DKD) marked by ...

Researchers from the National Institute for Physiological Sciences, Nagoya City University, and Tokyo Metropolitan Institute ...

Summary: For over a century, potassium ions were viewed as mere passengers in the brain—particles that flow through channels ...

Okazaki, Japan, 22 April 2026 – Potassium ions (K⁺) are essential for all cells and living organisms. Scientists have long believed that K⁺ merely ...

Multiple research fronts saw major advances on April 24, 2026, with AI models driving new capabilities in protein interaction prediction, automated protein design, and earthquake engineering ...

At AACR 2026, researchers discussed the promise and challenges of bringing AI-powered tools into cancer research and clinical ...

Dr. Simon Sumer explains how AI‑driven protein design is shortening development cycles, improving screening efficiency, and ...

For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those ...